menu
    • menu
    [{"orgOrder":0,"company":"Biocontrolled","sponsor":"Equillium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biocontrolled","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biocontrolled \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Biocontrolled \/ Biocon"}]

    Find Clinical Drug Pipeline Developments & Deals by Biocontrolled

    Menu

    Biocontrolled

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biocontrolled

                            Venezuela arrow
                            Luxepack
                            Not Confirmed

                            Biocontrolled

                            Venezuela arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itolizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Equillium

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial

                            Details : Itolizumab is a first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. Patients enrolled in EQUINOX trial will be randomized 1:1 to receive either itolizumab or placebo in addition to best supportive care for the treatment for...

                            Brand Name : EQ001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 29, 2020

                            Lead Product(s) : Itolizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Equillium

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth